Low-dose colchicine to prevent clots after TAVR
Treatments studied
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy clinical trials.
This study tests whether a low dose of colchicine, an anti-inflammatory medicine, can help prevent blood clots after a minimally invasive aortic valve replacement (TAVR). It is for people aged 60–85 who have had successful TAVR through the leg artery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 60 and 85 years old.
- You have had a TAVR (aortic valve replacement) through the leg artery successfully.
- You do not have severe kidney disease (creatinine clearance below 30 or needing dialysis).
- You do not have a serious liver condition (like cirrhosis or active hepatitis).
- You are not taking certain medications that can interact with colchicine (ask your doctor).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a low dose of colchicine, an anti-inflammatory medication, can help prevent bypass grafts from closing after heart surgery. You would take this medication for a set period after your coronary artery bypass graft (CABG) surgery.
This trial tests whether a low dose of the anti-inflammatory drug colchicine can help people who have recently had a heart attack or unstable angina. It aims to see if colchicine reduces the risk of future heart problems.
This study tests whether a low-dose medicine called colchicine can reduce inflammation and slow down artery blockages in people who have a specific gene change (TET2) and have recently had a heart attack. The goal is to see if it helps prevent future heart problems.
This trial is for people who had a heart attack and received a specific type of stent (Orsiro). It tests a combination of a single antiplatelet drug and colchicine to see if it helps prevent future heart problems. Colchicine is a medicine that reduces inflammation and might lower the risk of another heart attack.
This trial tests whether the drug colchicine can reduce the chance of developing atrial fibrillation (an irregular heart rhythm) after open-heart surgery. If it works, it could help you recover more smoothly.
This trial tests whether adding a targeted anti-inflammatory drug to standard care can prevent future heart attacks or strokes in people with high-risk chronic coronary artery disease. It is for people who have a moderate narrowing in a heart artery with a vulnerable plaque and signs of inflammation.
Hear when a new Transcatheter Aortic Valve Replacement trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.